Lilly Ventures — 2020 Investments

1 investments dated 2020 · listed companies and verified rows first · show all

ReadCoorreadcoor.com 𝕏Jan 2020 · $27M

Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.

BiotechDeep TechHardwareHealthtechCambridge, US

Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)

BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)

Co-investorsDecheng Capital LAV Lilly Asia Ventures Vivo Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.